Literature DB >> 19909749

Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection.

Brian J McMahon1, Dana Bruden, Michael G Bruce, Stephen Livingston, Carol Christensen, Chriss Homan, Thomas W Hennessy, James Williams, Daniel Sullivan, Hugo R Rosen, David Gretch.   

Abstract

BACKGROUND & AIMS: The factors associated with adverse outcome from hepatitis C virus (HCV) infection are incompletely understood. To determine the incidence and risk factors associated with the development of end-stage liver disease (ESLD) and liver-related death (LRD), we conducted a retrospective/prospective population-based study in a cohort of Alaska Native persons chronically infected with HCV from 1994 to 2005.
METHODS: We followed 960 persons prospectively for an average of 7.2 years and retrospectively for 12.1 years with data from medical records and serum samples. We compared data from subjects that were chronically infected with those who recovered from HCV infection, stratified by alcohol use. Survival models were used to examine factors associated with ESLD and LRD in chronically infected patients.
RESULTS: During prospective follow-up, 80 (8.8%) and 47 (5.2%) patients developed ESLD and LRD, respectively. In examining incidence per 100 person-years, no difference was found among heavy alcohol users in the incidence of LRD (2.28 versus 3.50; P = .34) or ESLD (3.21 versus 5.69; P = .13) in persons with chronic HCV compared with those recovered from HCV infection. In subjects that consumed <50 g alcohol/d, the incidences of LRD were 0.77 and 0.09 (P = .01) and of ESLD were 1.58 versus 0.36 (P = .002), respectively, in subjects with chronic infection versus those that recovered. Multivariate analysis showed that older age, heavy alcohol use, and HCV genotype 3 were associated with ESLD.
CONCLUSIONS: A history of heavy alcohol use is associated with the highest incidence of LRD and ESLD, regardless of whether patients are chronically infected or recover from HCV infection. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19909749     DOI: 10.1053/j.gastro.2009.10.056

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

1.  Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort.

Authors:  Dana J T Bruden; Brian J McMahon; Lisa Townshend-Bulson; Prabhu Gounder; Jim Gove; Julia Plotnik; Chriss Homan; Annette Hewitt; Youssef Barbour; Philip R Spradling; Brenna C Simons; Susan McArdle; Michael Bruce
Journal:  Hepatology       Date:  2017-05-22       Impact factor: 17.425

2.  Mortality caused by chronic liver disease among American Indians and Alaska Natives in the United States, 1999-2009.

Authors:  Anil Suryaprasad; Kathy K Byrd; John T Redd; David G Perdue; M Michele Manos; Brian J McMahon
Journal:  Am J Public Health       Date:  2014-04-22       Impact factor: 9.308

3.  Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs.

Authors:  Risha Irvin; Geetanjali Chander; Kathleen M Ward; Sean Manogue; Oluwaseun Falade-Nwulia; Juhi Moon; Catherine G Sutcliffe; Sherilyn Brinkley; Taryn Haselhuhn; Stephanie Katz; Kayla Herne; Lilian Arteaga; David L Thomas; Shruti H Mehta; Mark S Sulkowski
Journal:  J Viral Hepat       Date:  2020-01-07       Impact factor: 3.728

Review 4.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

5.  Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008.

Authors:  Bryce D Smith; Geoff A Beckett; Anthony Yartel; Deborah Holtzman; Nita Patel; John W Ward
Journal:  Am J Public Health       Date:  2014-01-16       Impact factor: 9.308

6.  HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Jawad Ilyas; Zhigang Duan; Hashem B El-Serag
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

Review 7.  Hepatitis C virus infection in the human immunodeficiency virus infected patient.

Authors:  Louise Nygaard Clausen; Lene Fogt Lundbo; Thomas Benfield
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

8.  Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death.

Authors:  Brian J McMahon; Dana Bruden; Lisa Townshend-Bulson; Brenna Simons; Phillip Spradling; Stephen Livingston; James Gove; Annette Hewitt; Julia Plotnik; Chriss Homan; Hannah Espera; Susan Negus; Mary Snowball; Youssef Barbour; Michael Bruce; Prabhu Gounder
Journal:  Clin Gastroenterol Hepatol       Date:  2016-10-17       Impact factor: 11.382

9.  Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study.

Authors:  Bryce D Smith; Anthony K Yartel; Katherine Krauskopf; Omar I Massoud; Kimberly A Brown; Michael B Fallon; David B Rein
Journal:  Clin Infect Dis       Date:  2015-01-16       Impact factor: 9.079

10.  HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study.

Authors:  Gregory D Kirk; Shruti H Mehta; Jacquie Astemborski; Noya Galai; Jonathan Washington; Yvonne Higgins; Ashwin Balagopal; David L Thomas
Journal:  Ann Intern Med       Date:  2013-05-07       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.